Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)†

Introduction Retroperitoneal sarcoma (RPS) is a rare disease accounting for 0.1%-0.2% of all malignancies. Management of RPS is complex and requires multidisciplinary, tailored treatment strategies at all stages, but especially in the context of metastatic or multifocal recurrent disease. Due to the rarity and heterogeneity of this family of diseases, the literature to guide management is limited. Methods The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG) is an international collaboration of sarcoma experts from all disciplines convened in an effort to overcome these limitations. The TARPSWG has compiled the available evidence surrounding metastatic and multifocally recurrent RPS along with expert opinion in an iterative process to generate a consensus document regarding the complex management of this disease. The objective of this document is to guide sarcoma specialists from all disciplines in the diagnosis and treatment of multifocal recurrent or metastatic RPS. Results All aspects of patient assessment, diagnostic processes, local and systemic treatments, and palliation are reviewed in this document, and consensus recommendations provided accordingly. Recommendations were guided by available evidence, in conjunction with expert opinion where evidence was lacking. Conclusions This consensus document combines the available literature regarding the management of multifocally recurrent or metastastic RPS with the practical expertise of high-volume sarcoma centers from multiple countries. It is designed as a tool for decision making in the complex multidisciplinary management of this condition and is expected to standardize management across centers, thereby ensuring that patients receive the highest quality care.

Robin L. Jones | J. Blay | J. Sicklick | N. Ahuja | E. Wardelmann | B. Dickson | C. Catton | S. Bonvalot | R. Gonzalez | F. van Coevorden | C. Raut | A. Italiano | R. Maki | W. Tap | A. D. Dei Tos | P. Rutkowski | E. Baldini | D. Kirsch | T. Delaney | J. Kane | R. Pollock | P. Hohenberger | P. Casali | R. Miceli | R. Maestro | A. Gronchi | R. Haas | S. Stacchiotti | S. Bagaria | T. Henzler | G. Lahat | W. Hartmann | Yoon-La Choi | S. Katz | W. V. van Houdt | M. Fiore | W. Al-Refaie | A. Miah | D. Strauss | C. Messiou | Shreyaskumar R Patel | D. Blazer | P. Ridgway | A. Frezza | C. Nessim | G. Grignani | B. Kasper | E. Stoeckle | Y. Schrage | F. Eilber | D. Gyorki | R. Canter | M. Angele | R. Andtbacka | P. Méeus | G. Beasley | Myles J. Smith | Kyo-Won Lee | V. Pillarisetty | S. Pasquali | M. Sbaraglia | S. L. Renne | A. Moreira | A. Hayes | J. Mullen | V. Grignol | B. Purgina | K. Cardona | R. Gladdy | C. Swallow | E. Pennacchioli | E. Palassini | J. A. Fernández | F. Barretta | A. Wagner | A. De Paoli | V. Quagliuolo | S. Sandrucci | T. Hamilton | P. Sargos | M. Albertsmeier | S. Radaelli | S. Ford | A. Desai | J. Jakob | A. J. Gelderblom | G. Mann | C. Colombo | M. Rastrelli | R. Sanfilippo | D. Callegaro | A. MacNeill | W. Tseng | B. Zakotnik | M. Gervais | W. V. D. van der Graaf | Vicente Olivares Ripoll | J. Åhlén | M. Novak | S. Burtenshaw | D. Eržen | Christopher Fletcher | Francoise Ducimitiere | Christina Lynn Roland | W. Nabil | Kim Sung Joo | S. Renne | P. Meeus | C. Fletcher

[1]  P Reichardt,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Abha A. Gupta,et al.  Randomized Controlled Trials in Soft Tissue Sarcoma: We Are Getting There! , 2017, Surgical oncology clinics of North America.

[3]  David R. Jones,et al.  Pulmonary metastasectomy with therapeutic intent for soft‐tissue sarcoma , 2017, The Journal of thoracic and cardiovascular surgery.

[4]  S. Bonvalot,et al.  Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  Robin L. Jones,et al.  Treatment of retroperitoneal sarcoma: current standards and new developments , 2017, Current opinion in oncology.

[6]  J. Blay,et al.  Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study , 2017, BMC Medicine.

[7]  A. Nakatsuka,et al.  Impact of tumor volume doubling time on post-metastatic survival in bone or soft-tissue sarcoma patients treated with metastasectomy and/or radiofrequency ablation of the lung , 2017, OncoTargets and therapy.

[8]  C. D. Fletcher,et al.  Erratum to: Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group , 2016, Annals of Surgical Oncology.

[9]  E. Keung,et al.  Surgical Management of Metastatic Disease. , 2016, The Surgical clinics of North America.

[10]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jonathan J. Lewis,et al.  PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Robin L. Jones,et al.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial , 2016, The Lancet.

[13]  C. Simone,et al.  Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection , 2016, Journal of surgical oncology.

[14]  P. Casali,et al.  Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma. , 2016, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[15]  S. Bonvalot,et al.  Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group , 2016, Annals of surgery.

[16]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[17]  F. Chibon,et al.  Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. , 2016, The Lancet. Oncology.

[18]  D. Ceppa Results of Pulmonary Resection: Sarcoma and Germ Cell Tumors. , 2016, Thoracic surgery clinics.

[19]  N. Mulet-Margalef,et al.  Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS) , 2015, Cancer Chemotherapy and Pharmacology.

[20]  F. Salvi,et al.  Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas. , 2015, Anticancer research.

[21]  Lesly A. Dossett,et al.  Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma , 2015, Journal of surgical oncology.

[22]  K. Hunt,et al.  Survival After Resection of Gastrointestinal Stromal Tumor and Sarcoma Liver Metastases in 146 Patients , 2015, Journal of Gastrointestinal Surgery.

[23]  Robin L. Jones,et al.  A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma , 2015, Clinical Sarcoma Research.

[24]  A. Gronchi,et al.  The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma , 2015, Journal of surgical oncology.

[25]  M. Neary,et al.  A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments , 2015, BMC Cancer.

[26]  M. Scorsetti,et al.  Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. , 2015, European journal of cancer.

[27]  J. Geschwind,et al.  Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival. , 2015, European journal of radiology.

[28]  R. Cameron,et al.  Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas. , 2015, The Journal of thoracic and cardiovascular surgery.

[29]  F. Bertucci,et al.  Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[30]  P. Terrier,et al.  Abdominal Desmoplastic Small Round Cell Tumor: Multimodal Treatment Combining Chemotherapy, Surgery, and Radiotherapy is the Best Option , 2015, Annals of Surgical Oncology.

[31]  R. Lamba,et al.  Diagnostic imaging of hepatic lesions in adults. , 2014, Surgical oncology clinics of North America.

[32]  G. Lang,et al.  Pulmonary metastasectomy for soft tissue sarcoma--report from a dual institution experience at the Medical University of Vienna. , 2014, European journal of cancer.

[33]  K. S. Hall,et al.  Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[35]  J. Blay,et al.  Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  E. Levine,et al.  Efficacy of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Management of Malignant Ascites , 2014, Annals of Surgical Oncology.

[37]  S. Strauss,et al.  Outcome after Radiofrequency Ablation of Sarcoma Lung Metastases , 2014, CardioVascular and Interventional Radiology.

[38]  Robin L. Jones,et al.  Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma , 2013, Sarcoma.

[39]  P. Choong,et al.  Retroperitoneal sarcomas: A review of disease spectrum, radiological features, characterisation and management , 2013, Journal of medical imaging and radiation oncology.

[40]  Giuseppe Rubini,et al.  18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up). , 2013, Clinical imaging.

[41]  M. Montesco,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal sarcomatosis: long-term outcome from a single institution experience. , 2013, Anticancer research.

[42]  C. Morosi,et al.  Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics , 2013, Clinical Cancer Research.

[43]  L. Mariani,et al.  Response to chemotherapy of solitary fibrous tumour: a retrospective study. , 2013, European journal of cancer.

[44]  K. Cardona,et al.  Multimodality therapy for advanced or metastatic sarcoma. , 2013, Current problems in cancer.

[45]  T. Treasure,et al.  Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data , 2012, BMJ Open.

[46]  J. Blay,et al.  Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  T. Nielsen,et al.  Pazopanib for metastatic soft-tissue sarcoma , 2012, The Lancet.

[48]  J. Blay,et al.  Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). , 2012, The oncologist.

[49]  T. Pawlik,et al.  Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. , 2012, Journal of the American College of Surgeons.

[50]  T. Demmy,et al.  Pulmonary metastasectomy for soft tissue sarcoma. , 2012 .

[51]  G. Salti,et al.  Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Sarcomatosis , 2012, Annals of Surgical Oncology.

[52]  G. Powell,et al.  Value of PET scan in patients with retroperitoneal sarcoma treated with preoperative radiotherapy. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[53]  L. Constine,et al.  Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. , 2010, International journal of radiation oncology, biology, physics.

[54]  C. Klodell Pulmonary Resection of Metastatic Sarcoma: Prognostic Factors Associated With Improved Outcomes , 2012 .

[55]  D. Sugarbaker,et al.  Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. , 2011, The Annals of thoracic surgery.

[56]  D. Steinbrüchel,et al.  Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  F. Petrella,et al.  A 10-Year Single-Center Experience on 708 Lung Metastasectomies: The Evidence of the “International Registry of Lung Metastases” , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[58]  A. Sudo,et al.  Clinical impact of the tumor volume doubling time on sarcoma patients with lung metastases , 2011, Clinical & Experimental Metastasis.

[59]  J. Maurel,et al.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Shrager,et al.  Improved Survival after Pulmonary Metastasectomy for Soft Tissue Sarcoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[61]  J. Roth,et al.  Progression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients. , 2011, Journal of the American College of Surgeons.

[62]  森田 達也 「緩和ケア」として行われた介入と副次的評価項目であることの限界 (論文を読み,理解する--Early palliative care for patients with metastatic non-small-cell lung cancer) , 2011 .

[63]  J. Wunder,et al.  Soft tissue sarcoma presenting with metastatic disease , 2011, Cancer.

[64]  J. Buckels,et al.  Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[65]  A. Ravaud,et al.  Lung Tumors Treated With Percutaneous Radiofrequency Ablation: Computed Tomography Imaging Follow-Up , 2011, CardioVascular and Interventional Radiology.

[66]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[67]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[68]  H. Fernando,et al.  Surgical and nonresectional therapies for pulmonary metastasis. , 2010, The Surgical clinics of North America.

[69]  M. Fiore,et al.  Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy? , 2010, Annals of Surgical Oncology.

[70]  T. Molnar,et al.  What Are the Considerations in the Surgical Approach in Pulmonary Metastasectomy? , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[71]  Robin L. Jones,et al.  Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[72]  C. Antonescu,et al.  Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  S. Sleijfer,et al.  Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom , 2010, European journal of cancer.

[74]  C. Poremba,et al.  Reexcision of Soft Tissue Sarcoma: Sufficient Local Control but Increased Rate of Metastasis , 2009, World Journal of Surgery.

[75]  K. Takeda,et al.  Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas , 2009, Cancer.

[76]  M. Sonobe,et al.  Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[77]  J. Kane,et al.  Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[78]  C. Moran,et al.  Management of primary pulmonary artery sarcomas. , 2009, The Annals of thoracic surgery.

[79]  M. Hochman,et al.  Bone and soft-tissue lesions: what factors affect diagnostic yield of image-guided core-needle biopsy? , 2008, Radiology.

[80]  L. Qin,et al.  Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft‐tissue sarcoma of the extremity , 2007, Cancer.

[81]  J. Blay,et al.  Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Quaas,et al.  Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. , 2007, Anticancer research.

[84]  T. Nicol,et al.  Complete hepatic resection of metastases from leiohyosarcoma prolongs survival , 1998, Journal of Gastrointestinal Surgery.

[85]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  K. Brown,et al.  Treatment of metastatic sarcoma to the liver with bland embolization , 2006, Cancer.

[87]  D. Jaeck,et al.  Hepatic Resection for Noncolorectal Nonendocrine Liver Metastases: Analysis of 1452 Patients and Development of a Prognostic Model , 2006, Annals of surgery.

[88]  T. Pawlik,et al.  Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. , 2006, Archives of surgery.

[89]  J. Blay,et al.  Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[90]  A. Meyer,et al.  Changes in Indication and Results After Resection of Hepatic Metastases From Noncolorectal Primary Tumors: A Single-Institutional Review , 2005, Annals of Surgical Oncology.

[91]  G. Ercolani,et al.  The Role of Liver Resections for Noncolorectal, Nonneuroendocrine Metastases: Experience With 142 Observed Cases , 2005, Annals of Surgical Oncology.

[92]  O. S. Nielsen,et al.  Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  G. Feder,et al.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project , 2003, Quality & safety in health care.

[94]  F. Cluzeau,et al.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project , 2003 .

[95]  O. S. Nielsen,et al.  Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. , 2003, European journal of cancer.

[96]  J. Kane,et al.  The Treatment and Outcome of Patients With Soft Tissue Sarcomas and Synchronous Metastases , 2002, Sarcoma.

[97]  E. Abdalla,et al.  Metastasectomy for limited metastases from soft tissue sarcoma , 2002, Current treatment options in oncology.

[98]  W. Jarnagin,et al.  Results of Hepatic Resection for Sarcoma Metastatic to Liver , 2001, Annals of surgery.

[99]  R. Benjamin,et al.  Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  J. Blay,et al.  Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. , 2001, European journal of cancer.

[101]  W. Richards,et al.  Sequential thoracic metastasectomy prolongs survival by re-establishing local control within the chest. , 2001, The Journal of thoracic and cardiovascular surgery.

[102]  M. Weiser,et al.  Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. , 2000, Journal of the American College of Surgeons.

[103]  P. Flemming,et al.  Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period. , 2000, Annals of surgery.

[104]  O. S. Nielsen,et al.  Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. , 2000, European journal of cancer.

[105]  M. Burt,et al.  Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. , 1999, Annals of surgery.

[106]  D. Kandioler,et al.  Long-term results after repeated surgical removal of pulmonary metastases. , 1998, The Annals of thoracic surgery.

[107]  U. Pastorino Lung metastasectomy: why, when, how. , 1997, Critical reviews in oncology/hematology.

[108]  M. Brennan,et al.  Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. , 1997, Surgery.

[109]  O. S. Nielsen,et al.  Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group study of 255 patients , 1996, Cancer.

[110]  P. Choong,et al.  Long-term survival in high-grade soft-tissue sarcoma - prognostic factors in synovial sarcoma. , 1995, International journal of oncology.

[111]  A. Rydholm,et al.  Size and timing of local recurrence predicts metastasis in soft tissue sarcoma. Growth rate index retrospectively analyzed in 134 patients. , 1995, Acta orthopaedica Scandinavica.

[112]  F. Sim,et al.  Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. , 1995, Acta orthopaedica Scandinavica.

[113]  F. van Coevorden,et al.  Repeated resection of recurrent pulmonary metastatic soft tissue sarcoma. , 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[114]  P. McCormack,et al.  Development and Treatment of Pulmonary Metastases in Adult Patients with Extremity Soft Tissue Sarcoma , 1993, Annals of surgery.

[115]  D. Saltzman,et al.  Aggressive metastasectomy for pulmonic sarcomatous metastases: a follow-up study. , 1993, American journal of surgery.

[116]  K. Kodama,et al.  Aggressive pulmonary metastasectomy for soft tissue sarcomas , 1993, Cancer.

[117]  C. Attinger,et al.  Selected benefits of thoracotomy and chemotherapy for sarcoma metastatic to the lung , 1993, Journal of surgical oncology.

[118]  N. Petrelli,et al.  Resection of lung metastases from soft-tissue sarcomas. A multivariate analysis. , 1992, Archives of surgery.

[119]  J. Roth,et al.  Five‐year survival after pulmonary metastasectomy for adult soft tissue sarcoma , 1992, Cancer.

[120]  S. Steinberg,et al.  Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma. , 1991, The Annals of thoracic surgery.

[121]  J. Roth,et al.  Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. , 1991, The Annals of thoracic surgery.

[122]  S. Steinberg,et al.  Metastasectomy for soft tissue sarcoma. Further evidence for efficacy and prognostic indicators. , 1989, The Journal of thoracic and cardiovascular surgery.

[123]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[124]  J. Roth,et al.  Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients , 1985, Cancer.